Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
ConclusionsBased on PFS and ORR results of this indirect meta-analysis, palbociclib, ribociclib, and abemaciclib are equally effective in either first- or second-line therapy for advanced ER + BC. They, however, ported different toxicity profiles.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Anemia | Breast Cancer | Cancer | Cancer & Oncology | Databases & Libraries | Endocrine Therapy | Study | Toxicology